ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis

Similar documents
Supplementary Appendix

R2R: Severe sepsis/septic shock. Surat Tongyoo Critical care medicine Siriraj Hospital

Healthcare-associated infections acquired in intensive care units

Q 1 (May-July 2016) Q 2 (August-October 2016) Q 3 (November 2016-January 2017)

ANWICU knowledge

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Scottish Surveillance of Healthcare Associated Infection Programme (SSHAIP) Health Protection Scotland (HPS) SSI Surveillance Protocol 7th Edition

Appendix. Supplementary figures and tables

Supplementary Online Content

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

Online Supplement for:

Supplementary appendix

Supplementary Online Content

Staging Sepsis for the Emergency Department: Physician

Admissions with severe sepsis in adult, general critical care units in England, Wales and Northern Ireland

MICROBIOLOGICAL TESTING IN PICU

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Bacteriemia and sepsis

NEONATAL SEPSIS. Dalima Ari Wahono Astrawinata Departemen Patologi Klinik, FKUI-RSCM

Treatment of febrile neutropenia in patients with neoplasia

5/1/2015 SEPSIS SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 INFECTION CAN BE CONFIRMED BY:

Hospital-acquired Pneumonia

Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID

INTRA-ABDOMINAL INFECTIONS

SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data

Blood cultures in ED. Dr Sebastian Chang MBBS FACEM

Usefulness of Procalcitonin in the management of Infections in ICU. P Damas CHU Sart Tilman Liège

Supplementary Appendix

Data Collection Tool. Standard Study Questions: Admission Date: Admission Time: Age: Gender:

PHYSIOLOGY AND MANAGEMENT OF THE SEPTIC PATIENT

Trial protocol - NIVAS Study

Unit II Problem 2 Pathology: Pneumonia

320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017

Clinical and Molecular Characteristics of Community- Acquired Methicillin-Resistant Staphylococcus Aureus Infections In Chinese Neonates

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Initial Resuscitation of Sepsis & Septic Shock

Microbiological diagnosis of infective endocarditis; what is new?

Sepsis is an important issue. Clinician s decision-making capability. Guideline recommendations

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP

What the ED clinician needs to know about SEPSIS - 3. Anna Morgan Consultant EM Barts Health

Streptococci facultative anaerobe

Chapter 5: Sepsis Stephen Lo

The EM Educator Series

Enhanced EARS-Net Surveillance REPORT FOR 2012 DATA

Pneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention. Basics of Infection Prevention 2-Day Mini-Course 2016

Is nosocomial infection the major cause of death in sepsis?

Discussion of Complex Clinical Scenarios and Variable Review ACS NSQIP Clinical Support Team

Antimicrobial Stewardship in Community Acquired Pneumonia

Chapter 16. Lung Abscess. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.

Influenza A (H1N1)pdm09 in Minnesota Epidemiology

Pathology of Pneumonia

SUPPLEMENTARY MATERIAL

Aciphin Ceftriaxone Sodium

Sepsis and Infective Endocarditis

Sepsis and Septicemia: Clear up Coding and Documentation Confusion october 2009

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Work-up of Respiratory Specimens Now you can breathe easier

Work up of Respiratory & Wound Cultures:

Fluorescence immunoassay Point of care test Wide range PCT. whole blood. plasma. serum

Pressure Injury Complications: Diagnostic Dilemmas

HOSPITAL INFECTION CONTROL

Pneumonia. Definition of pneumonia Infection of the lung parenchyma Usually bacterial

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Diagnosis of Ventilator- Associated Pneumonia: Where are we now?

JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections

National Healthcare Safety Network: Central Line-associated Bloodstream Case Studies Teresa C. Horan, MPH

CLIF Consortium. Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study

SEPSIS. Sepsis Dianna Foley, RHIA, CHPS. Sepsis Stats 3/3/2015

Enteric bacteria(pseudomonas+salmonella) Dr.Asem shihabi. Jumanah Nayef Abu Asbeh

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel

The Septic Patient. Dr Arunraj Navaratnarajah. Renal SpR Imperial College NHS Healthcare Trust

RETROSPECTIVE COMPARISON OF EMPYEMA THORACIS IN HIV INFECTED AND NON-INFECTED PATIENTS WITH REGARDS TO AETIOLOGY AND OUTCOMES

AXITAB-CV TAB. COMPOSITION :

Severe and Tertiary Peritonitis

Enhanced EARS-Net Surveillance 2017 First Half

Influenza-Associated Pediatric Deaths Case Report Form

Editor s note. Photo quiz. Volume 3, Issue 3. March 2016

Supplementary Online Content

Guideline for management of children & adolescents with pleural empyema

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012

Lab 4. Blood Culture (Media) MIC AMAL-NORA-ALJAWHARA 1

Effective Date: SPECIMEN COLLECTION FOR CULTURE OF BACTERIAL PATHOGENS QUICK REFERENCE

Sepsis or Severe Sepsis? Is there a right thing, and how do we do it?

Andrea Blotsky MDCM FRCPC General Internal Medicine, McGill University Thursday, October 15, 2015

Composite of pneumonia, re-intubation, or death within 30 days of randomisation.

Sepsis Awareness and Education

Key Points. Angus DC: Crit Care Med 29:1303, 2001

Pneumonia. Dr. Rami M Adil Al-Hayali Assistant professor in medicine

IDENTIFYING SEPSIS IN THE PREHOSPITAL SETTING

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

VAP Prevention bundles

JAMA. 2016;315(8): doi: /jama

Microbiology Specimen Collection Instructions. Table I Culture and Sensitivities/TB

New Surveillance Definitions for VAP

Mesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

(Peripheral) Temperature and microcirculation

Transcription:

Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions of infection in the ICU, modified from the ISF criteria (International sepsis forum consensus conference of infection in the ICU) Microbiologically confirmed: Probable: Possible: Pneumonia 1. Clinically present and isolation of a pathogen; (1) a probable etiologic agent from an uncontaminated specimen e.g. blood, pleural fluid, (2) respiratory secretions of a pathogen that does not colonize the upper airways, (3) a possible pathogen in high concentrations using quantitative cultures of a lower respiratory tract sample e.g. BAL, PSB or (4) positive serology. 2. Clinically present plus (1) detection of a likely pulmonary pathogen in respiratory secretions e.g. sputum, endotracheal aspirate or (2) quantitatively cultured BAL fluid or PSB but in concentrations below diagnostic threshold or (3) presence of a negative respiratory tract culture if collected within 72 hrs. after starting a new antibiotic regimen. 3. Low or moderate clinical suspicion but with microbiological or serological evidence of pneumonia. Catheterrelated infection 4. At least one peripheral positive blood culture and positive tip culture for the same pathogen. 5. A hub or exit site culture growing the same microorganism as peripheral blood 6. No positive blood culture but positive culture of tip, exit site or hub Secondary peritonitis 7. Isolation of one or more microbial pathogens found in the peritoneum or the blood > 24 hrs. after a gastrointestinal perforation of the stomach, oesophagus or duodenum, or any perforation of the small bowel distal the ligament of treitz. A penetrating abdominal wound or documented perforation that is surgically repaired within 12 hrs. o fits occurrence is not sufficient evidence. 8. Compatible clinical illness associated with documented evidence of perforation (free air in the abdomen on radiographic studies or surgical confirmation of peritoneal inflammation in the absence of microbiologically confirmed peritonitis). 9. Upper gastrointestinal perforation or penetrating abdominal trauma that is surgically repaired, or a Skin- and soft tissue infection 10. Isolation by culture of a microorganism from a wound or skin lesion that has drained pus, or from a skin aspirate or biopsy of the subcutaneous tissues of an erythematous skin lesion or wound. 11. Clinical and laboratory evidence (such as spreading erythema or drainage of purulent material on opening surgical wounds, or leucocytosis) of the presence of a skin and soft tissue infection based on radiographic, clinical and surgical findings without microbiological confirmation. 12.Clinical, laboratory or radiographic findings suggestive of a skin and soft tissue infection but with insufficient evidence to confirm Intra abdominal abscess 13. Clinical, radiographic and surgical confirmation of an inflammatory collection within the peritoneal space or surrounding structures with isolation of microbial pathogens from the fluid collection. The fluid collection needs to be under sterile technique or direct surgical observation with acquisition of culture material directly from the abscess cavity or the blood. 14. The presence of an abnormal collection of fluid in the intraabdominal contents or surrounding structures with evidence of inflammatory cells but with negative cultures from fluid accumulation or blood. 15. Clinical or radiographic evidence of an abnormal fluid accumulation within the abdominal contents or

finding of peritoneal fluid in the absence of microbiological confirmation. diagnosis. surrounding structures but without microbiologic or surgical confirmation.. Endocarditis 16. Typical microorganism consistent with infective endocarditis demonstrated by two separate blood cultures or histologic examination of a vegetation or a intracardiac abscess or single positive blood culture for Coxiella burnetti and echocardiogram positive for endocarditis Primary bloodstream infection 17. Microorganism in blood culture, not usually regarded as skin contaminant, i.e. diphteroids, Bacillus species, Proprionebacterium species, coagulasenegative staphylococci or micrococci or above mentioned skin contaminants cultured from two or more blood cultures drawn separately and the organism cultured is not related to infection at another site. Meningitis Urosepsis Secondary bloodstream infection 18. Cerebrospinal fluid (CSF) with elevated white blood cells, elevated proteins and/or decreased glucose and isolation of a microbial pathogen from a sample of the CSF using culture, PCR, direct microscopy or antigen detection. 19. Microorganism isolated from urine and from fluid other than urine or radiographic, surgical or histopathological evidence of infection in the urinary tract. 20. Microorganism in blood culture,not usually regarded as skin contaminant, i.e. diphteroids, Bacillus species, Proprionebacterium species, coagulase-negative staphylococci or micrococci. The organism cultured is related to an infection with the same organism at another site. Epiglottitis 21 Visualisation of the supraglottal region shows inflammatory oedema of the arytenoids, aryepiglottic folds and epiglottis and isolation of a pathogen or radiographic evidence of epiglottitis.

Table S2. SIRS and Sepsis classification Modified SIRS criteria Patients had to meet at least three of the following four criteria: 1 Core temperature of > 38 C (100.4 F) or < 36 C (96.8 F) 2 Heart rate of > 90 beats/min, except in patients with a medical condition known to increase the heart rate or those receiving treatment that would prevent tachycardia 3 Respiratory rate of > 20 breaths/min or a PaCO 2 of < 4.3 kpa (32 mm Hg) or the use of mechanical ventilation for an acute respiratory process 4 White Blood cell Count of > 12,000/mm 3 or < 4,000/mm 3 One or more of the following five criteria: Criteria for organ dysfunction 1 Cardiovascular dysfunction: Arterial systolic blood pressure < 90 mm Hg or mean arterial pressure < 70 mm Hg for at least 1 hour despite adequate fluid resuscitation, adequate intravascular volume status or the use of vasopressors in an attempt to maintain a systolic blood pressure of > 90 mm Hg or a mean arterial pressure of > 70 mm Hg 2 Kidney dysfunction: Urine output < 0.5 ml/kg of body weight/hour for 2 hour, despite adequate fluid resuscitation 3 Respiratory dysfunction: Ratio of PaO 2 to FiO 2 < 27 kpa 4 Hematologic dysfunction: Platelet count < 80,000/mm 3 or to have decreased by 50 % in the 3 days preceding enrolment 5 In the case of unexplained metabolic acidosis, the ph had to be < 7.30 or the base deficit had to be > 5.0 mmol/l in association with a plasma lactate level that was > 3.0 mmol/l Sepsis Syndrome, Severe Sepsis and Septic Shock Sepsis Syndrome: At least three SIRS criteria and a possible, probable or confirmed infection, as evidenced by the ISF criteria Severe Sepsis: Sepsis Syndrome and at least one criteria for organ dysfunction Septic Shock: Sepsis Syndrome and fulfilment of the criteria for cardiovascular dysfunction PaCO2 partial pressure of arterial carbon dioxide, PaO2 partial pressure of arterial oxygen, FiO2 fraction of inspired oxygen and ISF international sepsis forum consensus conference of infection in the ICU.

Table S3. Number of significant positive blood cultures and other cultures. Pathogen Blood culture (n=56) Other culture (n=58) Staph aureus 5 11 Klebsiella pneumoniae 1 6 Streptococcus pneumoniae 1 5 Escherichia coli 1 4 Haemophilus influenzae 0 7 Enterobacter cloacae 0 3 Streptococcus milleri 0 2 Pseudomonas aeruginosa 0 2 Streptococcus pyogenes 0 2 Bacteroides fragilis 0 1 Serratia marcescens 0 1 Proteus mirabilis 0 1 Moraxella catarrhalis 0 1 Mycoplasma pneumoniae 0 1

Table S4 Likelihood, primary site and severity of infection. n = 58 Time from ICU admission to antibiotic treatment, days 2.6 (1, 4) Likelihood of infection according to ISF Confirmed infection (ISF 1, 4, 7, 10, 13, 16, 17, 18, 19, 20) 38 (65.5 %) Probable infection (ISF 2, 5, 8, 11, 14) 13 (22.4 %) Possible infection (ISF 0, 3, 6, 9, 12, 15) 7 (12.1 %) Primary site of infection Pneumonia (ISF 1, 2, 3) 44 (75.9 %) Catheter-related infection (ISF 4, 5, 6) 1 (1.7 %) Peritonitis (ISF 7, 8, 9) 0 (0 %) Skin and soft-tissue infection (ISF 10, 11, 12) 4 (6.9 %) Intraabdominal abscess (ISF 13, 14, 15) 0 (0 %) Endocarditis (ISF 16) 1 (1.7 %) Primary bloodstream infection (ISF 17) 0 (0 %) Meningitis (ISF 18) 1 (1.7 %) Urosepsis (ISF 19) 1 (1.7 %) Unknown (ISF not applicable) 6 (10.3 %) Microbiological findings Positive blood culture 8 (14 %) Positive PBS or BAL 32 (55 %) Positive urine culture 6 (10 %) Positive CSF, tissue, abscess, endotracheal 28 (48 %) Any positive culture 47 (81 %) Gram stain negative growth in culture 26 (45 %) Worst SIRS/sepsis severity in infected patients in ICU No SIRS 2 (3.4 %) SIRS* 3 (5.2 %) Sepsis 4 (6.9 %) Severe sepsis 24 (41.4 %) Septic shock 25 (43.1 %) Worst SOFA/sepsis severity in infected patients in ICU <2 0 (0 %) 2-4 1 (2 %) 5-10 18 (31 %) 11-16 33 (57 %) 17-24 6 (10 %)

Vasopressor dependent & hyperlactatemia (>2 mmol/l) 31 (53 %) Median (IQR) or n (%). *SIRS before but not during possible, probable or confirmed infection.

Table S5. Univariable and multivariable logistic regression analysis, showing the association with having a possible, probable or confirmed bacterial infection on the day of antibiotic prescription. Univariable analysis Multivariable analysis Explanatory Obs Odds ratio P Odds ratio P a variable (95 % CI) (95 % CI) Female gender 110 0.35 (0.14-0.86) 0.02 0.7 (0.01-0.35) 0.001 APACHE II (per 110 1.09 (1.03-1.15) 0.003 1.13 (1.02-1.25) 0.02 point increment) GI/Liver disease 110 4.00 (0.81-19.77) 0.09 6.6 (0.53-82.36) 0.14 SIRS at admission 109 3.04 (1.12-8.20) 0.03 5.9 (0.98-35.16) 0.05 Calprotectin mg/l on day of antibiotic prescription 78 1.51 (1.16-1.98) 0.002 2.0 (1.32-3.14) 0.001 a Variables with a P < 0.10 in the univariable analysis were included in the multivariable analysis. APACHE II: Acute Physiology and Chronic health Evaluation II. GI/Liver: Gastrointestinal or liver disease. SIRS: Systemic Inflammatory response Syndrome.

Sensitivity analysis; in calculations below patients with possible and probable infection were excluded (ISF 0, 3, 6, 9, 12, 15 + ISF 2, 5, 8, 11, 14). Table S6. ROC area with 95% CI, optimal cut-off, sensitivity, specificity at the time of antibiotic prescription and one day before antibiotic prescription. In non-infected patients sampling was 48-72 hours and 24-48 hours post admission, respectively. P- value for the test of equality between the ROC area of each biomarker vs. calprotectin. Biomarker ROC area Cut-off Sensitivity Specificity P-value Diagnostic value of biomarker (same day as antibiotic prescription) White blood cell count 0.52 (0.39-0.65) 10.8 42 % 74 % 0.04 Procalcitonin 0.65 (0.48-0.81) 0.66 73 % 58 % 0.59 C-reactive protein 0.71 (0.58-0.84) 133 82 % 54 % 0.96 Calprotectin 0.70 (0.57-0.83) 3.5 55 % 90 % - Prognostic value of biomarker (One day before antibiotic prescription) White blood cell count 0.44 (0.31-0.57) 8.4 67 % 41 % 0.0006 Procalcitonin 0.53 (0.35-0.71) 0.77 58 % 58 % 0.06 C-reactive protein 0.69 (0.50-0.88) 130 58 % 94 % 0.34 Calprotectin 0.82 (0.70-0.94) 1.6 66 % 93 % -

Table S7. ROC area with 95 % CI, optimal cut-off, sensitivity, specificity at the time of antibiotic prescription and one day before antibiotic prescription. For a non-infected patient, the biomarker level obtained on the corresponding ICU day was selected using greedy matching. The same matched pairs were used for calculating diagnostic value and prognostic value. P-value for the test of equality between the ROC area of each biomarker vs. calprotectin. Biomarker ROC area Cut-off Sensitivity Specificity P-value Diagnostic value of biomarker (same day as antibiotic prescription) White blood cell count 0.50 (0.38-0.59) 10.8 41 % 67 % 0.003 Procalcitonin 0.70 (0.58-0.82) 0.68 65 % 65 % 0.97 C-reactive protein 0.67 (0.59-0.83) 121 77 % 52 % 0.46 Calprotectin 0.70 (0.60-0.80) 2.8 54 % 80 % - Prognostic value of biomarker (One day before antibiotic prescription) White blood cell count 0.48 (0.31-0.57) 8.9 57 % 47 % 0.007 Procalcitonin 0.61 (0.48-0.74) 0.55 62 % 67 % 0.68 C-reactive protein 0.61 (0.50-0.72) 73 73 % 48 % 0.31 Calprotectin 0.68 (0.57-0.78) 1.9 62 % 77 % -

0 10 20 30 Peak Calprotectin mg/l Supplementary Figures Figure S1. Peak calprotectin levels according to worst SIRS/sepsis severity during ICU stay. Tukey boxplot with dots representing outliers above 1.5 x IQR from the median. No SIRS SIRS Sepsis Severe sepsis Septic shock